Back to Agenda
Session 5: Multi-Stakeholder Perspectives on the Value and Future of Patient-Reported Outcomes (PROs) in Clinical Trials
Session Chair(s)
Thomas Morel, DrSc
Director, Patient-Centred Outcomes Research
UCB Biopharma, Belgium
Session 5: Multi-Stakeholder Perspectives on the Value and Future of Patient-Reported Outcomes (PROs) in Clinical Trials
Speaker(s)
PROs from a Patient Perspective
Roger Wilson
Sarcoma UK, United Kingdom
Patient Representative
PROs from a Trialist Perspective
Melanie Jane Calvert, PhD
University of Birmingham, United Kingdom
Professor of Outcomes Methodology, Director of the Centre for PROs Research
PROs from a Regulatory Science Perspective
Daniel O'Connor, DrMed, PhD, MS
Medicines and Healthcare products Regulatory Agency, United Kingdom
Medical Assessor
PROs from a Regulatory Science Perspective – focus on Neurology
Pavel Petrov Balabanov, MD, PhD
European Medicines Agency, Netherlands
Head of Therapies for Neurological and Psychiatric Disorders
PROs from an HTA Perspective
Caridad Pontes
Catalan Health System, Spain
Head, Pharmacotherapeutic Harmonization
PROs from an Outcomes Measurement Perspective
Antoine Regnault, PhD, MS
Modus Outcomes, France
Global Lead - Statistics
PROs from the Pharmaceutical Industry Perspective
Thomas Keeley, PhD, MSc
GlaxoSmithKline, United Kingdom
Director, Patient Centred Outcomes
Panel discussion with Q&A, including additional participation
Michelle Campbell, PhD
FDA, United States
Associate Director, Stakeholder Engagement and Clinical Outcomes, ON, OND, CDER
Have an account?